Author:
Heiss Brian L.,Geynisman Daniel M.,Martinez Elia,Wong Alvin S. C.,Yong Wei Peng,Szmulewitz Russell Z.,Stadler Walter M.
Funder
National Institute of General Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Yap TA, Carden CP, Attard G, de Bono JS (2008) Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 8(4):449–457
2. Caram ME, Borza T, Min H-S, Griggs JJ, Miller DC, Hollenbeck BK, Mukherjee B, Skolarus TA (2017) Early national dissemination of abiraterone and enzalutamide for advanced prostate cancer in Medicare part D. J Oncol Pract 13(8):e694–e702
3. Malangone-Monaco E, Foley K, Varker H, Wilson KL, McKenzie S, Ellis L (2016) Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014: results of an oncology EMR analysis. Clin Ther 38(8):1817–1824
4. FDA (Initial U.S Approval 2011) Zytiga (abiraterone) highlights of prescribing information. Supplement-33, dated 10/2/2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202379s031s033lbl.pdf. Accessed 2 Nov 2021
5. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28(9):1481
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献